WESTON, Fla., May 15, 2019 /PRNewswire/ -- ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing first-in-class drugs for inflammatory and renal diseases, is pleased to announce that three leading Nephrologists have joined their Scientific Advisory Board.
Sharon G. Adler, MD
Professor of Medicine, David Geffen School of Medicine at UCLA
Chief, Division of Nephrology and Hypertension at Harbor-UCLA Medical Center
Program Director, Nephrology Fellowship Training Program at Harbor-UCLA Medical Center
Gerald B. Appel, MD, FACP, FASN
Director Glomerular Kidney Center and Professor of Medicine, Columbia University Medical Center of The New York-Presbyterian Hospital
Debbie S. Gipson, MD, MS
Professor, Department of Pediatrics, University of Michigan
Director, Kidney Research Network Coordinating Center
"We are honored that nephrologists with the accomplishments of Drs. Adler, Appel, and Gipson are joining our scientific advisory board," stated Stephen C. Glover, ZyVersa's Co-founder, Chief Executive Officer, and President. "We are committed to developing transformative drug therapies for patients with kidney disease. Enlisting the insights and strategic guidance of our renowned scientific advisory board will help drive the timely success of our clinical development program."
Drs. Adler, Appel, and Gipson will be joining our current team of prominent scientific advisors: Alessia Fornoni, MD, PhD, Professor of Medicine and Chief, Katz Family Division of Nephrology and Hypertension, University of Miami Miller School of Medicine; Jonathan J. Hogan, MD, Assistant Professor of Medicine and Clinical Director of the Glomerular Disease Center, Perelman School of Medicine, University of Pennsylvania; Marlene Haffner, MD, MPH, Principal and Founder, Orphan Solutions and former Director of Orphan Products Development at FDA; and Pablo A. Guzman, MD, FAAC, Chief Medical Officer, ZyVersa Therapeutics.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have high unmet medical needs. Our clinical pipeline includes a phase 2a-ready asset, VAR 200, a cholesterol efflux mediator for treatment of focal segmental glomerulosclerosis (FSGS), and a novel inflammasome inhibitor with potential for multiple inflammatory diseases. For more information, please visit www.zyversa.com or contact the following:
SOURCE ZyVersa Therapeutics, Inc.